Suchergebnisse

<b><i>Background:</i></b> Knowledge about hereditary colorectal cancer (CRC) can aid cancer screening and prevention in high-risk patients. Genetic testing, once conducted primarily at academic centers, is now routinely performed in a variety of clinics. Nonacademic physicians may not be aware of hereditary CRC standards of care. <b><i>Methods:</i></b> From August to November 2012, a survey was administered to predominantly primary care physicians evaluating academic center affiliation, past training in genetics and knowledge regarding hereditary CRC. <b><i>Results:</i></b> One hundred forty physicians completed the survey. Knowledge of hereditary CRC was neither associated with academic affiliation nor with training during medical school or residency, but with continuing medical education (CME) training. Those with CME training were more likely to know that screening could be enhanced for patients with a hereditary cancer risk (OR = 4.49, 95% CI = 1.40-14.38) and that an individual with hereditary CRC would have different screening recommendations (OR = 7.49, 95% CI = 1.37-40.81). Residency training and CME training were associated with more frequent hereditary risk assessment. <b><i>Conclusion:</i></b> Genetics training may be associated with physicians' knowledge and assessment of hereditary CRC. Training at the CME level in particular may be integral to the delivery of genetic services in clinical practice.

National Institutes of Health (NIH) Monarch Initiative [NIH OD #5R24OD011883]; E-RARE 2015 program, Hipbi-RD (harmonizing phenomics information for a better interoperability in the RD field); Director, Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy under [DE-AC02-05CH11231]; Bundesministerium f ¨ur Bildung und Forschung (BMBF) [0313911]; Raine Clinician Research Fellowship (to G.B.); Stanley Institute for Cognitive Genomics at Cold Spring Harbor Laboratory (CSHL to G.J.L.); European Union Seventh Framework Programme [FP7/2007-2013] supported RD-Connect [305444], EURenOmics [2012-305608] and NeurOmics [2012-305121]; Fight for Sight and Retinitis Pigmentosa Fighting Blindness (to N.P.); National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital National Health Service Foundation Trust and UCL Institute of Ophthalmology (UK) (to V.C.); University of Kiel, by a grant from the German Research Foundation [HE5415/3-1 to I.H.] within the EuroEPINOMICS framework of the European Science Foundation and grants of the German Research Foundation [DFG, HE5415/5-1, HE5415/6-1], German Ministry for Education and Research [01DH12033, MAR 10/012] and by the German chapter of the International League against Epilepsy (DGfE); International League Against Epilepsy (ILAE to I.H.) within the Epilepsiome initiative of the ILAE Genetics Commission (www.channelopathist. net); National Library of Medicine [R44 LM011585-02 to M.S.]. BBAdV is funded by the Dutch Organisation for Health Research and Development (ZON-MW grants 912-12-109). Funding for open access charge: NIH [R24- OD011883]